Abstract
Twenty one evaluable patients with advanced colorectal carcinoma were treated with continuous infusion of spirogermanium at a median daily dose of 150 mg/m2 (range 120–210) for five consecutive days every 14 days. Treatments were accomplished by using outpatient infusion devices. Fifteen patients had not received any prior radiation therapy, immunotherapy, or chemotherapy. Nineteen patients were previously untreated with chemotherapy. Five patients had received prior immunotherapy with copovithane and only two patients had received radiation therapy prior to spirogermanium therapy. None of the patients achieved a complete or partial remission. Minor tumor regressions were observed in two patients, both were < 12 weeks in duration. The major toxicities included nausea and vomiting and neurologic side effects; however, the toxicity was completely reversible. Spirogermanium is not effective in the treatment of patients with advanced colorectal carcinoma.
Similar content being viewed by others
References
Rice LM, Wheeler JW, Geschickter CF: Spirans XXII. Synthesis of 4,4-dialkyl-4-germacyclohexnone and 8,8-dialkyl-8-germanazaspiro (4.5) decanes. J Heterocyclic Chem 11:1041–1047, 1974
Rice LM, Slavik M, Schein P: Clinical brochure: Spirogermanium (NSC-192965) National Cancer Institute, Bethesda, MD, 1977
Hill BT, Whatley SA, Bellamy AS, et al.: Cytotoxic effects and biological activity of 2-aza-8-germanspiro (4,5) decane-2-propranamine-8,8 dietyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro. Cancer Res 42:2852–2856, 1982
Legha SS, Ajani JA, Bodey GP: Phase I study of spirogermanium given daily. J Clin Oncol 1:331–336, 1983
Woolley PV, Ahlgren JD, Byrne PJ, Priego VM, Schein PS: A phase I trial of spirogermanium administered on a continuous infusion schedule. Invest New Drugs 2:305–309, 1984
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ajani, J.A., Faintuch, J.S., McClure, R.K. et al. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. Invest New Drugs 4, 383–385 (1986). https://doi.org/10.1007/BF00173512
Issue Date:
DOI: https://doi.org/10.1007/BF00173512